Genetically determining individualized clinical reference ranges for the biomarker tryptase can limit unnecessary procedures and unmask myeloid neoplasms.
Chovanec J, Tunc I, Hughes J, Halstead J, Mateja A, Liu Y, O'Connell M, Kim J, Park YH, Wang Q, Le QT, Pirooznia M, Trivedi N, Bai Y, Yin Y, Hsu AP, McElwee JJ, Lassiter S, Nelson C, Bandoh J, DiMaggio T, Selb J, Rijavec M, Carter MC, Komarow H, Sabato V, Steinberg JA, Hafer KM, Feuille E, Hourigan CS, Lack J, Khoury P, Maric I, Zanotti R, Bonadonna P, Schwartz LB, Milner JD, Glover S, Ebo DG, Korosec P, Caughey G, Brittain E, Busby B, Metcalfe DD, Lyons JJ.
Chovanec J, et al. Among authors: lassiter s.
Blood Adv. 2022 Sep 28:bloodadvances.2022007936. doi: 10.1182/bloodadvances.2022007936. Online ahead of print.
Blood Adv. 2022.
PMID: 36170795